Keyphrases
S100A9
100%
Brain Metastases
100%
Resistance Mechanisms
100%
Radiosensitive
100%
Whole Brain Radiotherapy
100%
Therapeutic Benefits
33%
Molecular Mechanism
16%
Brain Development
16%
Disease Progression
16%
Brain Lesions
16%
In Vivo Model
16%
Patient Selection
16%
Therapeutic Potential
16%
Clinical Impact
16%
Non-invasive Biomarkers
16%
Clinical Response
16%
Breast Adenocarcinoma
16%
Metastatic Lesions
16%
Unbiased Analysis
16%
Primary Melanoma
16%
Low-dose Radiation
16%
Molecular Frameworks
16%
Advanced Lung Adenocarcinoma
16%
Radiosensitization
16%
Therapeutic Toxicity
16%
Radiotherapy Resistance
16%
Actionable Target
16%
Medicine and Dentistry
Brain Metastasis
100%
Whole Brain Radiotherapy
100%
Biological Marker
33%
Mediator
16%
Low Drug Dose
16%
Nodular Melanoma
16%
Breast Adenocarcinoma
16%
Disease Exacerbation
16%
Spine
16%
Patient Selection
16%
Lung Adenocarcinoma
16%
Radiosensitizer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Metastasis
100%
Biological Marker
40%
Melanoma
20%
Breast Adenocarcinoma
20%
Disease Exacerbation
20%
Lung Adenocarcinoma
20%
Radiosensitizing Agent
20%
Biochemistry, Genetics and Molecular Biology
S100A9
100%
Mediator
33%
Low Drug Dose
33%
Radiosensitizer
33%